Document:

srne-ex103_472.htm

 

Exhibit 10.3

FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 23, 2017 (the “Fourth Amendment Effective Date”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), Concortis Biosystems, Corp., a Delaware corporation, Ark Animal Health, Inc., a Delaware corporation, TNK Therapeutics, Inc., a Delaware corporation, Sorrento Biologics, Inc., a Delaware corporation, Scintilla Pharmaceuticals, Inc., a Delaware corporation, LA Cell, Inc., a Delaware corporation, SiniWest Holding Corp., a Delaware corporation, Levena Biopharma US, Inc., a Delaware corporation, BioServ Corporation (formerly known as Sorrento BioServices, Inc.), a Delaware corporation, Scilex Pharmaceuticals Inc., a Delaware corporation, SNAN Holdco LLC, a Delaware limited liability company and each of their Qualified Subsidiaries (together with “Parent” hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties thereto as Lender, constituting the Required Lenders, and HERCULES CAPITAL, INC., formerly known as Hercules Technology Growth Capital, Inc., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, together with its successors and assigns in such capacity, “Agent”).

The Borrower, the Lender and Agent are parties to a Loan and Security Agreement dated as of November 23, 2016 (as amended by that certain First Amendment to Loan and Security Agreement dated as of December 27, 2016, that certain Second Amendment to Loan and Security Agreement dated as of March 2, 2017, that certain Third Amendment to Loan and Security Agreement dated as of March 15, 2017 and as may be further amended, restated or modified from time to time, the “Loan and Security Agreement”).  The Borrower has requested that the Lender agree to certain amendments to the Loan and Security Agreement.  The Lender has agreed to such request, subject to the terms and conditions hereof.

Accordingly, the parties hereto agree as follows:

SECTION 1Definitions; Interpretation.

(a)Terms Defined in Loan and Security Agreement.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.

(b)Interpretation.  The rules of interpretation set forth in Section 1.1 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

1

 

SECTION 2Amendments to the Loan and Security Agreement.

(a)The Loan and Security Agreement shall be amended as follows effective as of the Fourth Amendment Effective Date:

(i)Amended Definitions.  The following definition is hereby amended as follows:

“Fourth Amendment Repayment” has the meaning given to it in Section 2.2(d).

“Initial Fundraising Requirement” is hereby amended by replacing “March 23, 2017” with “April 14, 2017” therein.

(i)Section 2.2(d). Section 2.2(d) of the Loan and Security Agreement is hereby amended by adding the following sentence at the end of such section:  “On or prior to March 23, 2017, the Borrower shall have repaid Twenty Million Dollars ($20,000,000) in outstanding principal and unpaid interest thereon (the “Fourth Amendment Repayment”).  Such Fourth Amendment Repayment shall not be subject to the Prepayment Charge.”

(ii)Section 7.20. Section 7.20 of the Loan and Security Agreement is hereby amended by replacing “March 23, 2017” with “April 14, 2017” therein.

(iii)Section 7.21.  Section 7.21 of the Loan and Security Agreement is hereby amended by replacing “Forty-Five Million Dollars ($45,000,000)” with “Twenty Million Dollars ($20,000,000)” therein.

(iv)Exhibit F.  Exhibit F of the Loan and Security Agreement is hereby amended by replacing “$45,000,000” with “$20,000,000” therein and by replacing “$25,000,000” with “$20,000,000” therein.

(b)References Within Loan and Security Agreement.  Each reference in the Loan and Security Agreement to “this Agreement” and the words “hereof,” “herein,” “hereunder,” or words of like import, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment.

SECTION 3Conditions of Effectiveness.  The effectiveness of Section 2 of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:

(a)Partial Repayment. The Borrower shall have paid the Fourth Amendment Repayment.

(b)Fees and Expenses.  The Borrower shall have paid (i) all attorney fees and other costs and expenses then due in accordance with Section 5(e), and (ii) all other fees, costs and expenses, if any, due and payable as of the Fourth Amendment Effective Date under the Loan and Security Agreement (including, without limitation, the fee set forth in Section 2.10 of the Loan and Security Agreement).

2

 

(c)This Amendment.  Agent shall have received this Amendment, executed by Agent, the Lender and the Borrower.

(d)Representations and Warranties; No Default.  On the Fourth Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby:

(i)The representations and warranties contained in Section 4 shall be true and correct in all material respects on and as of the Fourth Amendment Effective Date as though made on and as of such date; and

(ii)There exist no Events of Default or events that with the passage of time would result in an Event of Default.

SECTION 4Representations and Warranties.  To induce Agent and Lender to enter into this Amendment, the Borrower hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; (b) that there has not been and there does not exist a Material Adverse Effect; and (c) that the information included in the Perfection Certificate delivered to Agent on the Effective Date remains true and correct.  For the purposes of this Section 4, any representations and warranties which relate solely to an earlier date shall not be deemed confirmed and restated as of the date hereof (provided that such representations and warranties shall be true, correct and complete in all material respects as of such earlier date).

SECTION 5Miscellaneous.

(a)Loan Documents Otherwise Not Affected; Reaffirmation.  Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  The Lender’s and Agent’s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.  The Borrower hereby reaffirms the grant of security under Section 3.1 of the Loan and Security Agreement and hereby reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Loan and Security Agreement, including without limitation any Term Loans funded on or after the Fourth Amendment Effective Date, as of the date hereof.

(b)Conditions.  For purposes of determining compliance with the conditions specified in Section 3, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Fourth Amendment Effective Date specifying its objection thereto.

3

 

(c)Release.  In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan and Security Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

(d)No Reliance.  The Borrower hereby acknowledges and confirms to Agent and the Lender that the Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.

(e)Costs and Expenses.  The Borrower agrees to pay to Agent on the Fourth Amendment Effective Date the out-of-pocket costs and expenses of Agent and the Lenders party hereto, and the fees and disbursements of counsel to Agent and the Lenders party hereto (including allocated costs of internal counsel), in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Fourth Amendment Effective Date or after such date.

(f)Binding Effect.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.  

(g)Governing Law.  This Amendment, the Loan and Security Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

4

 

(h)Complete Agreement; Amendments.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.  

(i)Severability of Provisions.  Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

(j)Counterparts.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

(k)Loan Documents. This Amendment shall constitute a Loan Document.

[Balance of Page Intentionally Left Blank; Signature Pages Follow] 

 

 

5

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.

 

		
	
BORROWER:

	
 

	
SORRENTO THERAPEUTICS, INC.

	
 
	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

		
	
CONCORTIS BIOSYSTEMS, CORP.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

		
	
ARK ANIMAL HEALTH, INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

		
	
SORRENTO BIOLOGICS, INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

[Signature Page to Fourth Amendment to Loan and Security Agreement (Sorrento/Hercules)]

 

		
		
	
TNK THERAPEUTICS, INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

		
	
SCINTILLA PHARMACEUTICALS, INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

		
	
LA CELL, INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
Chief Executive Officer

	
 
	
 

 

		
	
SINIWEST HOLDING CORP.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President

	
 
	
 

 

		
	
LEVENA BIOPHARMA US INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President & CEO

	
 
	
 

 

[Signature Page to Fourth Amendment to Loan and Security Agreement (Sorrento/Hercules)]

 

		
		
	
BIOSERV CORPORATION

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President

	
 
	
 

 

		
	
SCILEX PHARMACEUTICALS INC.

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
Chief Executive Officer

	
 
	
 

 

		
	
SNAN HOLDCO LLC

	
 

	
Signature:
	
/s/ Henry Ji, Ph.D.

	
 
	
 

	
Print Name:
	
Henry Ji, Ph.D.

	
 
	
 

	
Title:
	
President

	
 
	
 

 

 

 

[Signature Page to Fourth Amendment to Loan and Security Agreement (Sorrento/Hercules)]

 

		
		
	
AGENT:

	
 

	
HERCULES CAPITAL, INC.

	
 

	
Signature:
	
/s/ Jennifer Choe

	
 
	
 

	
Print Name:
	
Jennifer Choe

	
 
	
 

	
Title:
	
Assistant General Counsel

 

		
	
LENDER:

	
 

	
HERCULES CAPITAL, INC.

	
 

	
Signature:
	
/s/ Jennifer Choe

	
 
	
 

	
Print Name:
	
Jennifer Choe

	
 
	
 

	
Title:
	
Assistant General Counsel

 

[Signature Page to Fourth Amendment to Loan and Security Agreement (Sorrento/Hercules)]srne-ex104_473.htm

 

Exhibit 10.4

AMENDMENT NO. 3 TO STOCK PURCHASE AGREEMENT

This Amendment No. 3 to Stock Purchase Agreement (this “Amendment”) is dated as of March 14, 2017 by and between TNK Therapeutics, Inc., a Delaware corporation (the “Purchaser”), and Richard P. Junghans, M.D., Ph.D., as the Stockholders’ Representative (the “Representative”).

RECITALS

Whereas, the Purchaser, the Representative, BDL Products, Inc., a Delaware corporation (the “Company”), the former stockholders of the Company (the “Former Company Stockholders”) and Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”), are parties to that certain Stock Purchase Agreement, dated as of August 7, 2015 (the “Purchase Agreement”), pursuant to which the Former Company Stockholders sold, upon the terms and conditions set forth in the Purchase Agreement, all of the issued and outstanding shares of capital stock of the Company to the Purchaser;

Whereas, the Purchase Agreement provides, among other things, that if the Purchaser does not issue, for the principal purpose of capital-raising resulting in gross proceeds (individually or in the aggregate) to the Purchaser of at least $50,000,000, shares of its common stock or shares of a previously unissued series of preferred stock (a “Financing”), prior to March 15, 2016 (the “Financing Due Date”), then Sorrento will be obligated to issue shares of its common stock to the Former Company Stockholders;

Whereas, pursuant to Section 12.3 of the Purchase Agreement, the Purchase Agreement may not be amended, modified, altered or supplemented except by written agreement between the Purchaser and the Representative;

Whereas, an Amendment No. 1 to the Stock Purchase Agreement dated March 7, 2016 (the “First Amendment”) was entered into by the Purchaser and Representative (on behalf of the Former Stock Company Holders) to extend the Financing Due Date to September 15, 2016 (the “First Extended Financing Due Date”);

Whereas, an Amendment No. 2 to the Stock Purchase Agreement dated September 14, 2016 (the “Second Amendment”) was entered into by the Purchaser and Representative (on behalf of the Former Stock Company Holders) to further extend the Financing Due Date to March 15, 2017 (the “Second Extended Financing Due Date”);

Whereas, as of the date hereof, the Purchaser does not believe that it will complete a Financing prior to the Second Extended Financing Due Date (i.e., March 15, 2017); and

Whereas, the Purchaser and the Representative desire to amend the Purchase Agreement a third time to extend the period of time during which the Purchaser must complete a Financing before Sorrento will be obligated to issued shares of its common stock to the Former Company Stockholders, and to make certain other related conforming changes to the Purchase Agreement.

	
 
	
 
	
 

 

 

Now Therefore, in consideration of the mutual covenants and agreements contained herein, and with reference to the above recitals, the parties hereby agree as follows:

ARTICLE 1
AMENDMENTS

1.1Amendment to Section 1.4(b) of the Purchase Agreement.  The reference to “April 15, 2017” in Section 1.4(b) of the Purchase Agreement, as amended by the First Amendment, is hereby replaced with “October 15, 2017”.

1.2Amendment to Section 1.6(a) of the Purchase Agreement.  The first sentence of Section 1.6(a) of the Purchase Agreement, as amended and restated in the First Amendment and Second Amendment, is hereby amended and restated to read as follows:

“In the event that a Qualified Financing has occurred and the closing of the IPO has not occurred on or before September 15, 2017, as promptly as possible, and in no event later than September 30, 2017 (the “Repurchase Closing”), Sorrento shall purchase the Purchaser Stock Consideration from the Stockholders (the “Repurchase”).”

1.3Amendment to Section 5.14 of the Purchase Agreement.  The reference to “April 30, 2017” in Section 5.14 of the Purchase Agreement, as amended by the First Amendment, is hereby replaced with “October 30, 2017”.

1.4Amendment to Definition of “Qualified Financing” in Exhibit A to the Purchase Agreement.  The reference to “March 15, 2017” in the definition of “Qualified Financing” included in Exhibit A of the Purchase Agreement, as amended by the First Amendment, is hereby replaced with “September 15, 2017”.

ARTICLE 2
GENERAL PROVISIONS

2.1Definitions.  Capitalized terms in this Amendment but not otherwise defined in this Amendment shall have the meanings set forth in the Purchase Agreement.

2.2Continuing Effectiveness.  Except as modified by this Amendment, the Purchase Agreement shall remain in full force and effect and no party by virtue of entering into this Amendment is waiving any rights it has under the Purchase Agreement, and once this Amendment is executed by the parties hereto, all references in the Purchase Agreement to “the Agreement” or “this Agreement,” as applicable, shall refer to the Purchase Agreement as modified by this Amendment.

2.3Successors and Assigns.  The provisions of this Amendment shall apply to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the parties to this Amendment.

2.4Governing Law.  This Amendment shall be governed by and construed in accordance with the internal laws (and not the law of conflicts) of the State of California.

	
 
	
2
	
 

 

 

2.5Counterparts.  This Amendment may be executed in several counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same instrument, and shall become effective when counterparts have been signed by each of the parties to this Amendment and delivered to the other parties to this Amendment; it being understood that all parties to this Amendment need not sign the same counterparts.

[Signature Page Follows]

 

 

	
 
	
3
	
 

 

 

In Witness Whereof, the parties have executed this Amendment as of the date first above written.

 

	
 
	
THE PURCHASER:

	
 
	
 

	
 
	
TNK THERAPEUTICS, INC.

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
By:
	
/s/ Henry Ji, Ph.D.

	
 
	
Name:
	
Henry Ji, Ph.D.

	
 
	
Title:
	
Chief Executive Officer

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
THE REPRESENTATIVE:

	
 
	
 

	
 
	
 

	
 
	
 

	
 
	
/ Richard P. Junghans, M.D., Ph.D.

	
 
	
RICHARD P. JUNGHANS, M.D., Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]